This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael F. Holick, PhD, MD

Arch Dermatol. 1989;125(12):1692-1697.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Psoriasis remains the scourge for at least 50 million people worldwide. Although there are a variety of therapies available to patients with this affliction including methoxsalen plus ultraviolet light (PUVA), methotrexate, UVB light, topical and intralesional corticosteroids, retinoids, and cyclosporine, to date there is no truly safe and effective therapy for this often debilitating disease.^1,2 From a historical perspective, many treatments for this affliction have resulted from folklore medicine, or serendipitous empirical observations. The cause for psoriasis is unknown, although the proximate event is a hyperproliferation of the epidermis.³ As a result, most therapies have been designed to in some way alter the proliferative activity of epidermal cells, but in the manner that is often harmful to them. The recent development of retinoids for the treatment of psoriasis suggested the possibility of developing drugs that have specific physiologic and pharmacologic actions on epidermal cells. However, enthusiasm for retinoids . . . [Full Text PDF of this Article]

Author Affiliations
Vitamin D, Skin, and Bone Research Laboratory Boston University School of Medicine 80 E Concord, M-1013 Boston, MA 02118

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?